-
Clinical Ophthalmology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia
(2314) Views (473) Full article downloads
Authors: Nazimul Hussain, Taraprasad Das, Rohit Khanna, LS Mohan Ram, Kallukuri Sumasri
Published Date January 2007
Volume 2007:1(4) Pages 483 - 488
DOI: http://dx.doi.org/10.2147/OPTH.S
Nazimul Hussain1, Taraprasad Das1, Rohit Khanna2, LS Mohan Ram1, Kallukuri Sumasri1
1Smt. Kanuri Santhamma Retina Vitreous Centre, 2ICARE, L.V. Prasad Eye Institute, Andhra Pradesh, India
Background: To report the 12 months follow up results of verteporfin therapy for subretinal neovascularization (SRNV) associated with type 2A parafoveal telangiectasia (PFT).
Methods: A Prospective interventional case series. Patients who completed 12 months follow up following photodynamic dynamic therapy with verteporfin for subretinal neovascularistion with Type 2A PFT were studied. All patients underwent visual acuity assessment with ETDRS letter acuity chart at 4 meters, slit lamp biomicroscopy, fundus fluorescein angiography and photography. Treatment protocol of TAP study was followed. The follow up schedule was every month for 3 months and then every 3 months thereafter until 12 months. Primary outcome measure was the change in visual acuity and secondary outcome measure was the mean treatment rate. Improvement was defi ned as ≥ 10 letters gain, stabilization as ± 10 letters and deterioration as 10 letters loss.
Results: Twelve eyes of 7 patients received photodynamic therapy with verteporfin for SRNV with Type 2A PFT. Initial mean letter acuity was 25.4 and 23.4 at 12-months (p = 0.7). At 12 months, one eye had 10 letters gain, 2 eyes had ≥ 10 letters loss and 9 had stabilized vision (± 10 letters). The mean number of treatment was 2.6. Ten (83.3%) of 12 eyes had retinal pigment epithelial collateral change, observed at the end 12 months.
Conclusion: Photodynamic therapy with verteporfin is effective in stabilization of vision in SRNV associated with type 2A PFT.
Keywords: subretinal neoveascularisation, verteporfin, photodynamic therapy, parafoveal telangiectasia
Readers of this article also read:
Candida endophthalmitis: A critical diagnosis in the critically ill
Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
Cystoid macular edema
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Erratum
A case of recurrent bloody tears
- Journal Indexing
See where all the Dove Press journals are indexed
- Interested in being a peer-reviewer?
Click here to register.
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- A computer-based anaglyphic system for the treatment of amblyopia




